Key Distinctions Between Influenza A and Influenza B

Virology and Classification

The CDC classifies influenza A viruses into subtypes based on the surface antigens hemagglutinin (H) and neuraminidase (N); 16 H subtypes and 9 N subtypes have been identified in nature. 1, 2
According to the CDC, currently circulating influenza A subtypes in humans are H1N1 and H3N2, which are responsible for seasonal epidemics. 2
The CDC notes that influenza B viruses are not divided into subtypes; instead they are grouped into two genetic lineages, Yamagata and Victoria. 1
Both influenza B lineages co‑circulate during most influenza seasons, as reported by the CDC. 1

Evolutionary Dynamics and Pandemic Potential

The CDC states that influenza A undergoes antigenic drift markedly faster than influenza B, due to frequent point mutations during replication. 1, 2, 3
Conversely, influenza B evolves more slowly, showing a reduced rate of antigenic drift compared with influenza A. 1, 2, 3
Only influenza A can cause pandemics through antigenic shift—major genetic reassortment between distinct viral strains, especially between human and avian viruses—according to CDC guidance. 1, 2
The CDC cites the 2009 H1N1 pandemic as a prime example of influenza A’s pandemic capability, where a novel virus emerged with limited pre‑existing immunity in the population. 1

Clinical Presentation and Epidemiology

The CDC reports that influenza A and B produce clinically indistinguishable illness, characterized by abrupt onset of fever, myalgia, headache, malaise, non‑productive cough, sore throat, and rhinitis. 4, 2, 3
In pediatric patients, both virus types commonly cause otitis media, nausea, and vomiting, per CDC data. 2, 3
The CDC notes that influenza A and B have similar pathogenic potential in humans and co‑circulate during seasonal epidemics. 4

Transmission and Infectious Period

Both influenza A and B spread primarily via respiratory droplets expelled during coughing and sneezing, according to CDC recommendations. 2
The CDC specifies that the incubation period for both viruses is 1–4 days (average ≈2 days). 2, 3
Adults are infectious from one day before symptom onset through approximately five days after onset for either virus type, as outlined by the CDC. 2

Immunity and Vaccine Considerations

The CDC emphasizes that antibodies generated against one influenza type provide limited or no protection against the other type. 1, 2, 3
Even within the same type, antibody to one antigenic variant may not protect against a newly emerging variant of the same subtype or lineage, per CDC findings. 1, 2
The CDC recommends that seasonal influenza vaccines include both circulating A subtypes (H1N1 and H3N2) and at least one B lineage; historically, a mismatch between the vaccine B component and the circulating B lineage occurred in 5 of the past 10 seasons. 1

Diagnostic Considerations

Because symptoms alone cannot reliably differentiate influenza A from B, the CDC advises laboratory confirmation (e.g., RT‑PCR or rapid antigen testing) for definitive diagnosis. 2

Influenza Virus Types and Characteristics

Introduction to Influenza Types

Influenza viruses are categorized into three main types: influenza A, influenza B, and influenza C, with influenza A and B being responsible for epidemic human disease and causing the most significant morbidity and mortality worldwide 5, 6

Influenza A Characteristics

Influenza A viruses are further categorized into subtypes based on two surface antigens: hemagglutinin (H) and neuraminidase (N) 7, 5, 6
Since 1977, influenza A (H1N1) viruses, influenza A (H3N2) viruses, and influenza B viruses have been in global circulation 5, 6
Influenza A viruses undergo more rapid antigenic changes (antigenic drift) than influenza B viruses, leading to frequent seasonal epidemics 5, 6
More dramatic changes called "antigenic shift" can occur in influenza A, resulting in pandemic potential when a new subtype emerges 6

Influenza B Characteristics

Influenza B viruses are not categorized into subtypes but are separated into two distinct genetic lineages: Yamagata and Victoria 5, 6
Influenza B viruses undergo antigenic drift less rapidly than influenza A viruses 5, 6

Clinical Presentation and Epidemiology

Uncomplicated influenza illness is characterized by abrupt onset of constitutional and respiratory symptoms including fever, myalgia, headache, severe malaise, nonproductive cough, sore throat, and rhinitis 8, 9
The incubation period for influenza is 1-4 days, with an average of 2 days 10, 8
Persons can be infectious starting the day before symptoms begin through approximately 5 days after illness onset; children can be infectious for a longer period 8, 9
Annual epidemics of influenza typically occur during fall or winter months, but peak activity can occur as late as April or May 5, 6

Treatment and Prevention

Most seasonal influenza A (H1N1) virus strains tested from the United States and other countries have developed resistance to oseltamivir 6, 11
Annual influenza vaccination remains the cornerstone for prevention of influenza and its complications 7

Influenza A vs. Influenza B: Virology, Transmission, Immunity, and Vaccine Recommendations

Viral Classification and Structure

Influenza A viruses are categorized into subtypes based on hemagglutinin (H) and neuraminidase (N) antigens; the currently circulating human subtypes are H1N1 and H3N2. (CDC MMWR Recommendations) 12
Influenza B viruses are not divided into subtypes; they are separated into two co‑circulating genetic lineages, Yamagata and Victoria. (CDC MMWR Recommendations) 12

Evolutionary Dynamics and Pandemic Potential

Antigenic drift occurs markedly faster in influenza A than in influenza B, making A the primary driver of seasonal epidemics. (CDC MMWR Recommendations) 12
Influenza B evolves more slowly, exhibiting a reduced rate of antigenic drift compared with influenza A. (CDC MMWR Recommendations) 12
The 2009 H1N1 pandemic illustrates influenza A’s capacity for pandemic emergence via antigenic shift, which requires an animal reservoir (aquatic birds). (CDC MMWR Recommendations) 12

Transmission Characteristics

Both influenza A and B are transmitted mainly through respiratory droplets expelled during coughing or sneezing. (CDC MMWR Recommendations) 13
The incubation period for both viruses ranges from 1 to 4 days, with an average of approximately 2 days. (CDC MMWR Recommendations) 13
Adults are infectious from one day before symptom onset until about five days after onset for either virus type. (CDC MMWR Recommendations) 13
Children may remain infectious for more than 10 days after symptom onset for both virus types. (CDC MMWR Recommendations) 13

Immunologic Cross‑Protection

Antibodies generated against one influenza type (A or B) provide limited or no protection against the other type because of distinct surface antigens. (CDC MMWR Recommendations) 12
Within the same influenza type, antibodies to one antigenic variant may not protect against newly emerging variants of the same subtype or lineage. (CDC MMWR Recommendations) 12

Vaccine Considerations

Historical trivalent influenza vaccines, which contained only one B lineage, mismatched the circulating B lineage in 5 of 10 seasons between 2001 and 2011. (CDC MMWR Recommendations) 12
Quadrivalent influenza vaccines now include both B lineages (Yamagata and Victoria) to mitigate the mismatch problem. (CDC MMWR Recommendations) 12

Evidence‑Based Summary of Influenza A vs. Influenza B in Children (2025‑2026)

Epidemiology & Circulating Strains

Influenza A and B cause clinically indistinguishable illness with comparable severity in hospitalized children, but influenza A evolves more rapidly, can cause pandemics, and currently includes the H1N1pdm09 and H3N2 subtypes, whereas influenza B is limited to the Victoria lineage after the global disappearance of Yamagata in 2020. 14
The 2024‑2025 trivalent vaccine contains both circulating influenza A subtypes (H1N1pdm09 and H3N2). 14
For the 2024‑2025 season, the H3N2 vaccine component was updated (egg‑based A/Thailand/8/2022‑like; cell‑based/recombinant A/Massachusetts/18/2022‑like), while the H1N1pdm09 component remained unchanged (egg‑based A/Victoria/4897/2022‑like; cell‑based/recombinant A/Wisconsin/67/2022‑like). 14
Only the Victoria lineage of influenza B circulates globally; the Yamagata lineage has not been detected since 2020 and has been removed from U.S. seasonal vaccines. 14, 15
The Victoria lineage component of the 2024‑2025 vaccine (B/Austria/1359417/2021‑like) remains unchanged. 14

High‑Risk Pediatric Populations

Children younger than five years (especially those under two) and those with underlying medical conditions have an increased risk of hospitalization and complications from both influenza A and B. 14, 15
High‑risk conditions include chronic pulmonary disease (e.g., asthma, cystic fibrosis), cardiovascular disease, immunosuppression, neurologic disorders, severe obesity, and diabetes. 14

Diagnostic & Subtyping Practices

Subtyping is performed to differentiate H1N1 from H3N2 within influenza A and to determine the lineage (Victoria vs. Yamagata) for influenza B. 14

Antiviral Treatment Recommendations

For the 2024‑2025 season, antiviral treatment guidelines are simplified and do not differ between influenza A and B infections. 14
Neuraminidase inhibitors (oseltamivir and zanamivir) are effective against both influenza A and B viruses. 16

Vaccine Effectiveness

Influenza vaccination prevented an estimated 116 deaths among children aged 6 months to 17 years during the 2022‑2023 season. 16
In children 6 months to 8 years, vaccine effectiveness (VE) across recent seasons ranged from 23 %–59 % for H1N1pdm09, 23 %–34 % for H3N2, and 39 %–51 % for B/Victoria. 17
In adolescents 9 – 17 years, VE was lower: –20 % to 29 % for H1N1pdm09, 29 %–40 % for H3N2, and 34 %–43 % for B/Victoria. 17
Historically, up to 80 % of influenza‑associated pediatric deaths occurred in children who were unvaccinated or only partially vaccinated. 16
Overall VE against influenza‑associated death was 65 % (95 % CI 54‑74 %) in all children and 51 % (95 % CI 31‑67 %) in children with underlying conditions. 16

Vaccination Coverage & Implementation

During the 2023‑2024 season, 53.9 % of children 6 months to 17 years received influenza vaccination, representing an 8.5‑percentage‑point decline compared with May 2020. 14
Coverage disparities were observed: non‑Hispanic Black children had the lowest uptake (49.1 %); rural children (39.9 %) lagged behind suburban (53.7 %) and urban (59.5 %) peers. 14
Co‑administration of the influenza vaccine with other recommended immunizations, including the monoclonal antibody nirsevimab, is emphasized to improve overall protection. 14

Key Differences Between Influenza A and Influenza B and Their Clinical Implications

Viral Classification and Circulation

The Centers for Disease Control and Prevention (CDC) classifies influenza A viruses by two surface antigens—hemagglutinin (H) and neuraminidase (N)—with 16 H and 9 N subtypes identified in nature, although only H1N1 and H3N2 currently circulate in humans 18.
Influenza B viruses are not divided into subtypes; they exist as two genetic lineages—Victoria and Yamagata—that co‑circulate during most influenza seasons [18][19].
Both influenza A (H1N1, H3N2) and influenza B have been co‑circulating globally since 1977 [18][19].

Evolutionary Dynamics and Pandemic Potential

Influenza A undergoes antigenic drift markedly faster than influenza B, driving seasonal epidemics and requiring yearly vaccine reformulation 18.
Influenza B evolves more slowly, showing a reduced rate of antigenic drift compared with influenza A [18][19].
Only influenza A can cause pandemics through antigenic shift—major genetic reassortment between distinct viral strains, especially between human and animal (avian) viruses—because influenza A has a natural reservoir in wild aquatic birds 18.
The 2009 H1N1 pandemic illustrates influenza A’s capacity to generate a novel virus with limited pre‑existing immunity in the population 18.

Immunity and Cross‑Protection

Antibodies generated against one influenza type (A or B) provide limited or no protection against the other type due to distinct surface antigens [18][19].
Even within the same influenza type, antibodies to one antigenic variant may not protect against newly emerging variants of the same subtype or lineage 18.

Vaccine Strategy

Historical trivalent influenza vaccines that contained only a single B lineage mismatched the circulating B lineage in 5 of 10 seasons between 2001 and 2011, prompting the development of quadrivalent vaccines that include both B lineages 18.